RECURRENT MALIGNANT SOLID NEOPLASM
Clinical trials for RECURRENT MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for RECURRENT MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat cancers: olaparib targets IDH mutations
Disease control OngoingThis study tests the drug olaparib in people with advanced solid tumors (including brain tumors and bile duct cancer) that have IDH1 or IDH2 mutations. The goal is to see if olaparib can shrink or slow the growth of these cancers. About 89 participants will receive the drug, and …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
Precision drug ivosidenib tested in kids with tough IDH1 cancers
Disease control OngoingThis study tests a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have either returned or not responded to standard treatments. The goal is to see if the drug can shrink tumors. Only 3 participants were enrolled,…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
Targeted drug shows promise for kids with rare, Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called larotrectinib in children and young adults (ages 1 to 21) whose advanced or recurrent solid tumors, lymphoma, or histiocytic disorders have a specific genetic change called an NTRK fusion. The drug works by blocking enzymes that help cancer cells gr…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
New hope for rare childhood cancers: immunotherapy combo shows promise
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults whose rare cancers (like atypical teratoid/rhabdoid tumors or epithelioid sarcoma) have returned or not responded to treatment. These cancers lack certain genes, making them hard to tre…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 00:46 UTC
-
New hope for kids with rare cancers: drug blocks tumor growth
Disease control OngoingThis study tests a drug called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to standard therapy. The drug works by blocking enzymes that help tumors grow and form blood vesse…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:58 UTC
-
New targeted drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis study tests a drug called selpercatinib in children and young adults (ages 1 to 21) whose cancers have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients with advanced solid…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis study tested the drug ensartinib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers had come back or stopped responding to treatment and had specific gene changes (ALK or ROS1). The goal was to see if the drug could shrink o…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for kids with resistant cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had spread, returned, or stopped responding to treatment. The drug targets tumors with specific changes in FGFR genes. The main goal was to see if the drug could shrink or stop t…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control TerminatedThis early-stage trial tests a combination of three drugs—ZEN003694, nivolumab, and ipilimumab—in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combination can shrink or stabilize the canc…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Childhood cancer immunotherapy trial pulled before starting
Disease control TerminatedThis study was designed to test two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with cancers that returned or didn't respond to treatment and have many genetic mutations. The goal was to see if the combination could shrink tumors or help patients l…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New drug cocktail targets Hard-to-Treat cancers in kids and young adults
Disease control OngoingThis early-phase trial tested a combination of three drugs—dasatinib, temsirolimus, and cyclophosphamide—in 14 children and young adults with advanced solid tumors that had spread, returned, or stopped responding to standard treatments. The main goals were to find the safest dose…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New hope for hard-to-treat cancers? drug targets tumors with unstable genes
Disease control OngoingThis study tests the drug pembrolizumab in 21 adults with advanced solid tumors that have specific gene mutations (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or control the cancer. Pembrolizumab is a type of immunotherapy that helps the immune system…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests the safety and best dose of a drug called copanlisib combined with immunotherapy drugs (nivolumab, with or without ipilimumab) in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The goal is to find a dose t…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New hope for kids with returning cancers: drug blocks tumor growth
Disease control OngoingThis study tests an experimental drug called elimusertib in children and young adults whose solid tumors have returned or not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors by blocking enzymes that cancer cells need to …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New hope for kids with hard-to-treat cancers: targeted pill attacks faulty gene pathway
Disease control OngoingThis study tests the drug ulixertinib in about 20 children and teens whose advanced solid tumors, lymphoma, or related blood disorders have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the cancer. Participants must have already …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
Honest placebo: a sugar pill that fights cancer fatigue?
Symptom relief OngoingThis study tests whether an open labeled placebo—a pill that patients know contains no active drug—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply believing in treat…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 12, 2026 13:40 UTC
-
New combo targets cancer fatigue: exercise plus steroid shows promise
Symptom relief OngoingThis study tests whether adding a steroid drug called dexamethasone to a physical activity program can better reduce severe fatigue in people with advanced cancer. About 99 participants will be assigned to exercise alone or exercise plus the drug. The goal is to see if the combin…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 11, 2026 20:49 UTC
-
Money stress in cancer care: new study tests financial coaching
Symptom relief OngoingThis study tests whether a financial navigation program can reduce money-related stress for cancer patients and their caregivers. About 331 adults with advanced cancer or blood cancers will receive either financial coaching or usual care. The goal is to see if this help lowers fi…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Symptom relief
Last updated May 11, 2026 20:48 UTC
-
New combo aims to fight cancer fatigue
Symptom relief OngoingThis study tests whether a drug called anamorelin, combined with physical activity and nutritional counseling, can lessen severe fatigue in people with advanced solid tumors that have spread or come back. About 129 participants will receive the drug and support for several weeks.…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 11, 2026 20:39 UTC
-
Gene test trial aims to outsmart advanced cancers
Knowledge-focused OngoingThis study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to standard therapy are enrolled. The goal is to see if targe…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 17, 2026 00:46 UTC
-
Gene test trial aims to personalize cancer care for kids
Knowledge-focused OngoingThis study screens children and young adults (ages 1-21) with advanced solid tumors, lymphomas, or related disorders that have not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be targeted by cert…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 17, 2026 00:44 UTC
-
Which method works best for delivering palliative care to cancer patients?
Knowledge-focused OngoingThis study looks at two different ways to provide palliative care—a type of care that helps with symptoms and stress—to people with advanced cancer and their caregivers. About 208 patients and their caregivers will take part. The goal is to see which method helps more patients co…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: University of Rochester NCORP Research Base • Aim: Knowledge-focused
Last updated May 17, 2026 00:44 UTC
-
Brain waves reveal if unresponsive patients hear loved ones in final days
Knowledge-focused TerminatedThis study uses a brain wave test (EEG) to check if cancer patients who appear unresponsive in their last days can still hear or feel. Researchers will measure brain activity before and after speaking to them. The goal is to help families and doctors understand what patients may …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC
-
Cancer weight loss study also targets caregiver stress
Knowledge-focused OngoingThis study measures how often cancer patients in a supportive care clinic experience cachexia (unintentional weight loss and appetite loss) and examines the emotional toll on both patients and their primary caregivers. Researchers will track weight changes and use questionnaires …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC
-
Expert tumor board aims to unlock genetic secrets for advanced cancer patients
Knowledge-focused OngoingThis study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors receive treatments that match their cancer's genetic makeup. About 1,284 patients will take part, and their doctors will either use the t…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated May 14, 2026 12:05 UTC